Showing 6 posts of 6 posts found.


Top Ten most popular articles on this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on over the last seven …

Sanofi’s arthritis treatment Kevzara secures NICE recommendation

September 25, 2017
Sales and Marketing Kevzara, NICE, Sanofi, pharma, pharmaceutical, rheumatoid arthritis, sarilumab

Sanofi, along with its speciality care global business unit Sanofi Genzyme, are celebrating the news that NICE has passed its …


New potential blockbuster RA treatment enters European market

June 27, 2017
Sales and Marketing AbbVie, Humria, Kevzara, Regeneron, Sanofi

The world’s biggest selling drug, AbbVie’s Humira with $16 billion in sales last year, has a new rival in the …

Sanofi and Regeneron score FDA approval for arthritis

May 23, 2017
Manufacturing and Production, Sales and Marketing FDA, Kevzara, arthritis, sarilumab

The FDA has awarded Sanofi and Regeneron’s Kevzara (sarilumab) approval for the treatment of moderate to severely active rheumatoid arthritis …


EU recommendation for Sanofi and Regeneron’s arthritis treatment

April 24, 2017
Sales and Marketing Kevzara, NICE, sarilumab

Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …

Latest content